Many patients with triple-negative breast cancer (TNBC) have recurrence of their disease after an initial response to chemotherapy because the cancer cells have become resistant to treatment. TNBC has a lower survival rate because of this pattern of resistance and there are no targeted agents to treat this form of breast cancer.

Researchers at Vanderbilt University have found a powerful new genetic risk factor for breast cancer.

The Vanderbilt Commodores Women’s Basketball team will be decked out in pink uniforms when they take the home court this Sunday, Feb. 10, at 3 p.m., in a matchup against the Kentucky Wildcats.

Most triple-negative breast cancer patients who were treated with chemotherapy to shrink the tumor prior to surgery still had multiple genetic mutations in their tumor cells, according to a study by Vanderbilt-Ingram Cancer Center (VICC) investigators.

The machinery that builds the characteristic shape of epithelial cells suppresses breast cancer formation and metastasis in a mouse model.

Two newly identified gene variants linked to breast cancer may aid in predicting disease risk and targeting screening and prevention strategies.